Development of Glucose Transporter (GLUT) Inhibitors.

Autor: Reckzeh ES; Department of Chemical Biology Max Planck Institute of Molecular Physiology Otto-Hahn-Str. 11 44227 Dortmund Germany.; Department Chemistry and Chemical Biology TU Dortmund University Otto-Hahn-Str. 4a 44227 Dortmund Germany., Waldmann H; Department of Chemical Biology Max Planck Institute of Molecular Physiology Otto-Hahn-Str. 11 44227 Dortmund Germany.; Department Chemistry and Chemical Biology TU Dortmund University Otto-Hahn-Str. 4a 44227 Dortmund Germany.
Jazyk: angličtina
Zdroj: European journal of organic chemistry [European J Org Chem] 2020 May 03; Vol. 2020 (16), pp. 2321-2329. Date of Electronic Publication: 2019 Nov 28.
DOI: 10.1002/ejoc.201901353
Abstrakt: The discovery of novel compound classes endowed with biological activity is at the heart of chemical biology and medicinal chemistry research. This enables novel biological insights and inspires new approaches to the treatment of diseases. Cancer cells frequently exhibit altered glycolysis and glucose metabolism and an increased glucose demand. Thus, targeting glucose uptake and metabolism may open up novel opportunities for the discovery of compounds that differentiate between normal and malignant cells. This review discusses the different chemical approaches to the development of novel inhibitors of glucose uptake through facilitative glucose transporters (GLUTs), and focusses on the most advanced and potent inhibitor classes known to date. GLUT inhibitors may find application not only in the treatment of cancer, but also of other proliferative diseases that exhibit glucose addiction.
(© 2019 The Authors. Published by Wiley‐VCH Verlag GmbH & Co. KGaA.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje